Accolade (NASDAQ:ACCD) issued its earnings results on Wednesday. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.44), MarketWatch Earnings reports. Accolade had a negative return on equity of 18.32% and a negative net margin of 44.02%. The company had revenue of $73.29 million during the quarter, compared to analyst estimates of $70.37 million. During the same period in the previous year, the company posted ($0.47) earnings per share. The company’s quarterly revenue was up 99.2% on a year-over-year basis.
Shares of ACCD opened at $39.93 on Friday. The firm has a market capitalization of $2.64 billion, a price-to-earnings ratio of -21.47 and a beta of 1.76. The company has a debt-to-equity ratio of 0.64, a quick ratio of 2.71 and a current ratio of 2.71. The business’s fifty day moving average price is $45.03 and its two-hundred day moving average price is $47.28. Accolade has a 52 week low of $32.87 and a 52 week high of $65.25.
An institutional investor recently raised its position in Accolade stock. Morgan Stanley raised its position in Accolade, Inc. (NASDAQ:ACCD) by 91.0% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 613,564 shares of the company’s stock after buying an additional 292,317 shares during the period. Morgan Stanley owned about 0.93% of Accolade worth $33,323,000 as of its most recent filing with the SEC. 67.98% of the stock is currently owned by institutional investors and hedge funds.
Accolade Company Profile
Accolade, Inc develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists.
Receive News & Ratings for Accolade Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accolade and related companies with MarketBeat.com's FREE daily email newsletter.